Market Newsdesk

Oakland, Calif., May 04, 2021 (GLOBE NEWSWIRE) — Deem, a leading mobile and cloud technology provider for the corporate travel industry, today announced its first Canadian partnership with travel management company (TMC) Worldgo. The corporate TMC was searching for a modern travel booking and management platform that includes a robust mobile application, and found the Etta solution from Deem offers the functionality its clients require.

“Full mobile performance — offering air, hotel, and car booking and management with accessibility features — is way past due for the business travel industry,” said Deem President David Grace. “By continuing to focus on the traveler’s user experience and needs, our mobile-first approach with Etta is transforming travel for employees, their companies and TMCs. It’s exciting to welcome our first Canadian TMC partner to our journey.”

“We were looking for a platform that includes a user-friendly interface and full mobile capability,” said Eric Sakawsky, co-founder, Worldgo. “Etta offers so much more than  outstanding features for travelers. Its flexibility, especially with regard to choice for expense platforms, is going to excite business decision-makers, too. A complete solution that benefits the business and that travelers want to use is an easy choice to make.”

The Etta platform was introduced by Deem in February, 2021. A full redesign of its Work Fource software, Etta was created using a human-centered design and mobile-first approach and offers an intuitive, consumer-like booking and management solution.

Etta for iOS meets the Web Content Accessibility Guidelines (WCAG 2.0) level AA compliance. It is available now on the Apple App Store, with an Android version expected later this year. See what Etta can do at https://www.deem.com/products/etta.

 

 

About Worldgo

Worldgo is a value-based travel management company founded in Vancouver, Canada in May 2015. After 15 years in the travel industry, Worldgo’s co-founders went into business together to look at corporate travel from a different perspective. Growing quickly, a key fundamental to their success has been outstanding personal service, commitment to technology, and complete transparency. Worldgo understands what it means to mitigate risk, to stay in line with budgets, and to be available when plans change. It will never mislead a customer for its own benefit and has proven that the corporate travel industry is ripe for disruption from the traditional (that means old) approach. Proudly Canadian, Worldgo likes doing good business and is committed to serving clients on their terms. Learn more at www.Worldgo.ca

  

About Deem

Deem is on a mission to transform travel. Starring Etta, its mobile-first, corporate travel booking and management platform, Deem offers employees everything they need to easily make the right travel decisions for themselves and their company. Deem’s travel technology plugs into major travel agencies and expense solution providers, empowering more corporate customers and the world’s largest travel management companies.

Deem is a wholly owned and independently run subsidiary of Enterprise Holdings. The company is headquartered in Oakland, California, with offices in Dublin, Ireland and Bangalore, India. Learn more at Deem.com.

 

Diana Brandon
Deem
4155908414
[email protected]

Austin, TX, May 04, 2021 (GLOBE NEWSWIRE) — QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation nuclear medicines for the treatment of cancer and related diseases, announced today that it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial of Samarium-153 DOTMP (CycloSam^®) in patients with bone cancer. The IND submission was submitted fully electronically, was compliant with all current FDA electronic document requirements, and was accepted for review by the FDA.

“This IND submission is an important accomplishment for QSAM as we continue to advance the development of CycloSam for the treatment of several types of primary and metastatic bone cancers,” stated Douglas R. Baum, the Company’s CEO and Co-Founder. “We look forward to commencing this study and additional clinical trials to demonstrate the safety and efficacy of CycloSam in patients with primary and secondary bone cancer.”

The first proposed clinical trial included in the IND is a dose escalation and dose finding study of CycloSam to treat solid tumor(s) in the bone or metastatic to the bone. A wide group of all tumors metastatic to the bone from prostate, lung, and breast cancer are proposed to be eligible for this clinical trial.

In parallel with this regulatory submission, the Company has contracted with a well-established contract research organization (CRO) and is actively recruiting investigators and clinical trial sites to participate in this study, and expects to begin enrolling patients mid-year. The FDA has already cleared an investigator-initiated IND for CycloSam for the treatment of osteosarcoma, and a second single-patient IND in 2020 for a bone marrow ablation procedure prior to stem cell transplantation.

A
bout QSAM Biosciences:

QSAM Biosciences, Inc. holds the worldwide license for CycloSam^® (Samaium-153 DOTMP), a clinical-stage novel radiopharmaceutical meant to treat different types of bone cancer and related diseases. QSAM’s initial technology is Samarium-153 DOTMP, aka CycloSam^®, a clinical-staged bone targeting radiopharmaceutical​ developed by IsoTherapeutics Group LLC, leaders in the nuclear medicine space who also developed FDA-approved and commercially available Quadramet^® (Samarium-153 EDTMP), indicated for pain palliation. CycloSam was assigned to IsoTherapeutics Group’s subsidiary, IGL Pharma, Inc.

CycloSam^® has already demonstrated preliminary safety and efficacy in animal studies and a single patient FDA-cleared successful human trial performed in 2020. This nuclear technology uses low specific activity Samarium-153 (resulting in far less europium) and DOTMP, a chelator which is believed to eliminate off-target migration and targets sites of high bone turn over making it an ideal agent to treat osteosarcoma or other bone metastases. Osteosarcoma is the most common malignant bone tumor among children and adolescents. Because of its ability to deliver radiation to the skeletal system, it is also believed to be an effective agent to perform bone marrow ablation as pre-conditioning for bone marrow transplantation. This drug candidate utilizes an FDA approved radioisotope combined with a novel chelant that has demonstrated increased efficacy and decreased side effects in animal models. Further, CycloSam^® utilizes a streamlined, just-in-time manufacturing process. Given these factors, management believes there is a strong pathway to commercialization.

CycloSam^® is cleared by the FDA under an investigator initiated IND to commence human dosing in patients with osteosarcoma and bone metastasis. CycloSam^® was also cleared by FDA and successfully used under a single-patient IND to perform bone marrow ablation prior to allogenic marrow transplantation (BMA/T) in 2020.

Legal Notice Regarding Forward-Looking Statements: This news release contains “Forward-looking Statements”. These statements relate to future events or our future financial performance. These statements are only predictions and may differ materially from actual future results or events. We disclaim any intention or obligation to revise any forward-looking statements whether as a result of new information, future developments or otherwise. There are important risk factors that could cause actual results to differ from those contained in forward-looking statements, including, but not limited to our ability to fully commercialize our technology, risks associated with changes in general economic and business conditions, actions of our competitors, the extent to which we are able to develop new products and markets, the time and expense involved in such development activities, the ability to secure additional financing, the ability to consummate acquisitions and ultimately integrate them, the level of demand and market acceptance of our products, and changes in our business strategies. This is not an offering of securities and securities may not be offered or sold absent registration or an applicable exemption from the registration requirements.

Contact

David L. Kugelman
Atlanta Capital Partners LLC
T: (404) 856-9157
[email protected]
www.atlcp.com

Guilford, CT, May 04, 2021 (GLOBE NEWSWIRE) — Fast Company Magazine has recognized Hyperfine’s category-defining Swoop™ Portable MR Imaging System as a World Changing Idea with honorable mentions in two categories: World Changing Ideas of North America and World Changing Ideas in Health. 

Swoop™ offers unprecedented accessibility, immediacy, and convenience for patients and clinicians alike—it wheels directly to a patient’s bedside, plugs into a standard electrical outlet, and uses an Apple iPad® for control. Images display within minutes, enabling critical decision-making across clinical settings such as neurointensive care units, emergency departments, pediatrics, and more. Designed to complement fixed conventional MRI systems, Hyperfine can train new users on operation, device navigation, and safety in about 30 minutes. As easy to own as it is to use, the complete Swoop™ system costs less than the annual service contract for most current fixed MRI systems.

“Conventional MRIs are an essential diagnostic tool, but they are expensive to own and maintain, logistically cumbersome, and uncomfortable for patients. Swoop™ addresses these challenges by delivering MR imaging capabilities directly to a patient’s bedside, providing clinicians with immediacy and convenience that conventional MRI systems can’t offer,” commented Dr. Khan Siddiqui, Hyperfine’s Chief Medical Officer. “We are committed to delivering equitable healthcare to patients across the clinical spectrum and around the world, and this recognition from Fast Company as a World Changing Idea further validates our passion and drive to make MR imaging accessible and cost-effective.”

Now in its fifth year, the World Changing Ideas Awards showcase innovative products and brave concepts that make the world better. A panel of eminent Fast Company editors and reporters selected winners and finalists from a pool of more than 4,000 entries from around the world based on feasibility and the potential for impact. With the goals of awarding ingenuity and fostering innovation, Fast Company draws attention to ideas with great potential, helping them expand their reach to inspire more people to start working on solving the problems that affect us all.

“There is no question our society and planet are facing deeply troubling times. So, it’s important to recognize organizations that are using their ingenuity, impact, design, scalability, and passion to solve these problems,” says Stephanie Mehta, editor-in-chief of Fast Company. “Our journalists, under the leadership of senior editor Morgan Clendaniel, have discovered some of the most groundbreaking projects that have launched since the start of 2020.”

About MR Imaging and the Swoop™ Portable MR Imaging System

MRI (magnetic resonance imaging) uses a powerful magnetic field, radio waves, and a computer to create detailed pictures of the body’s internal structures, like the brain and skull. Doctors use these images to diagnose a variety of medical conditions. However, fixed conventional MRI systems can be inconvenient and inaccessible for providers and patients, especially when time is critical. Transport to the MR suite demands complicated scheduling coordination, moving patients, and, often, 4- to 6-hour patient backlogs—all of which compromise the utility of MRI as a diagnostic tool in time-sensitive settings. Furthermore, high capital investments, electrical power needs, and significant maintenance requirements present barriers to adoption across all populations, acutely so for developing countries and rural geographies. 

The Swoop™ Portable MR Imaging System addresses limitations of current imaging technologies and makes MRI accessible anytime, anywhere, to any patient. In August 2020, Swoop™ received market-ready FDA clearance for portable MR imaging of the brain and head for patients of all ages and received additional clearance for its deep learning Advanced AI Applications image analysis software in January 2021. 

Leading organizations have recognized Hyperfine’s Swoop™ Portable MR Imaging System as one of the most innovative health care technologies available today. Swoop™ won the American College of Emergency Physicians (ACEP) 2020 incubatED Medical Device Innovation Challenge as a solution that will shape the future of emergency medicine. Aunt Minnie named Hyperfine as one of two finalists for Best New Radiology Vendor in its 2020 Minnies Awards. The company also received the Best Practices Product Innovation Award from Frost & Sullivan, describing the disruptive technology as a “massive leap forward to democratizing MRI.” Most recently, Swoop™ was selected as a CES 2021 Innovation Awards Honoree. 

About Hyperfine Research

Hyperfine’s mission is to make MRI accessible to every patient, regardless of income or resources. Anytime. Anywhere. Hyperfine designed the Swoop™ Portable MR Imaging System to overcome patient transport and dedicated room requirements associated with fixed conventional MRI systems. The Swoop™ system plugs into a standard electrical outlet and, uses an Apple iPad® for control, and produces images at a patient’s bedside within minutes, allowing care teams to gain clinical information quickly. Fierce Medtech recently recognized Hyperfine as a 2020 Fierce 15 company for its innovative and creative approach to developing solutions for healthcare providers and patients. Hyperfine is part of 4Catalyzer, a portfolio of health technology companies with facilities in Connecticut, New York City, Palo Alto, California, and Taiwan.

 

www.hyperfine.io.

###

Attachment

• swoop image for use oct 2020 png small

Chris Ward
Hyperfine
1-866-SWOOP-MR
[email protected]

VANCOUVER, British Columbia, May 04, 2021 (GLOBE NEWSWIRE) — Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or “Core One”) a biotechnology research and development life sciences enterprise focused on advancing psychedelic medicines to market, is pleased to announce that it has completed the acquisition (the “Transaction”) of Akome Biotech Ltd. (“Akome”). With this strategic acquisition, the scope of Core One’s psychedelics’ bio-pharma research and development division will broaden to include drug formulations that effectively target and change underlying processes at the root of neurological disorders, and/or prevent further neurological damage that result from the disorders.

What distinguishes Akome’s approach from other companies focused on the psychedelic treatment of neurological disorders, is their proprietary cGMP drug formulations which are comprised of psychedelic compounds and plant bioactives. Through data mapping, Akome has identified what is believed to be powerful combinations of psychedelics and plant bioactives, active pharmaceutical ingredients (APIs) which activities seem to be complementary and/or synergistic.

Currently Akome has 4 provisional matter of composition patents filed with the United States Patent and Trademark Office for these plant bioactive-psychedelic drug formulations, all of which target different disorders: 2 DMT-based, for addressing Parkinson’s Disease, and Ischemic Stroke, respectively; one (1) psilocybin-based, for addressing Alzheimer’s Disease; and one (1) ketamine-based, for addressing depression.

Akome has an assembled team of renowned clinical research specialists, as well as medical research professionals, and has processes in place to ensure its proprietary formulations are of the highest quality, developed within short timelines, are cost effective, and are regulatory compliant.

Joel Shacker, CEO of the Company stated “Closing on Akome is an important step for the Company, as we have added an outstanding asset and a strong team. The drug formulations being developed could address the needs of millions of patients globally. By combining plant bioactives with psychedelic compounds, this company is revolutionizing psychedelic drug development.”

In consideration for all of the outstanding share capital of Akome, the Company has issued 3,500,000 common shares to the existing shareholders of Akome. Following issuance, the shares are subject to the terms of a pooling arrangement, during which time they may not be transferred or traded without the prior consent of the Company.

The Company is at arms-length from Akome and each of its shareholders. The Transaction neither constitutes a fundamental change for the Company, nor has it resulted in a change of control of the Company, within the meaning of applicable securities laws and the policies of the Canadian Securities Exchange.

The Company will also issue 100,000 common shares to each of three arms-length third-parties who introduced the Transaction to the Company (the “Finder’s Shares”), as well as 35,000 common shares as an administration fee (the “Administrative Shares”) to each of two parties that provided administrative support in connection with the Transaction. The Finder’s Shares and Administrative Shares are subject to a four-month hold from the date of issuance pursuant to the policies of the Canadian Securities Exchange.

About Core One Labs Inc.

Core One is a biotechnology research and technology life sciences enterprise focused on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy. Core One has developed a patent pending thin film oral strip (the “technology”) which dissolves instantly when placed in the mouth and delivers organic molecules in precise quantities to the bloodstream, maintaining excellent bioavailability. The Company intends to further develop and apply the technology to psychedelic compounds, such as psilocybin. Core One also holds an interest in medical clinics which maintain a combined database of over 275,000 patients. Through these clinics, the integration of its intellectual property, R&D related to psychedelic treatments and novel drug therapies, the Company intends to obtain regulatory research approval for the advancement of psychedelic-derived treatments for mental health disorders.

Core One Labs Inc.

Joel Shacker
Chief Executive Officer

FOR MORE INFORMATION, PLEASE CONTACT:
[email protected]
1-866-347-5058

Cautionary Disclaimer Statement:

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions, and expectations. They are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Such factors include, among other things: risks and uncertainties relating to the Company’s limited operating history and the need to comply with strict regulatory regulations. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.

In addition, psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act (Canada) and it is a criminal offence to possess substances under the Controlled Drugs and Substances Act (Canada) without a prescription or authorization. Health Canada has not approved psilocybin as a drug for any indication. Core One does not have any direct or indirect involvement with illegal selling, production, or distribution of psychedelic substances in jurisdictions in which it operates. While Core One believes psychedelic substances can be used to treat certain medical conditions, it does not advocate for the legalization of psychedelics substances for recreational use. Core One does not deal with psychedelic substances, except within laboratory and clinical trial settings conducted within approved regulatory frameworks.

MINNEAPOLIS, May 04, 2021 (GLOBE NEWSWIRE) — Icario, the healthcare industry’s leading health action company, is pleased to announce that CVC Capital Partners (“CVC”), a leading global private equity firm, has acquired a majority interest in the company through the CVC Growth Partners II fund. The investment will be used to fuel Icario’s next phase of growth; financial terms were not disclosed.

The news comes at an exciting time for Icario, which rebranded earlier this year following the merger of market leaders Revel and NovuHealth. CVC will help Icario accelerate its business roadmap as it continues to build innovative solutions for its customers, which include many of the most trusted health plans in the United States.

“With CVC’s support, Icario is ideally positioned to bring our mission to more people through our shared vision for the business,” said Steve Wigginton, CEO of Icario. “We have been fortunate to benefit from the insight and leadership of our founders and early investors, and we look forward to our next chapter led by a team and a firm with a strong reputation for taking organizations to the next level.”

“Icario’s proprietary technology, data science, and behavioral insights drive highly valuable actions,” said Aaron Dupuis, partner at CVC Growth Partners. “We have followed the Icario story for some time as part of our long-standing efforts in member engagement, and we look forward to working with the Icario team to accelerate initiatives to bring even more member engagement innovation to Icario’s impressive customer base of more than 50 leading healthcare payers.”

“Engaging consumers in their health has never been more important than it is today,” said Fazle Husain, Partner and Head of U.S. Healthcare at CVC. “We see significant tailwinds for Icario as plans increasingly focus on coordinating member communications to drive member satisfaction, better health outcomes and lower cost of care.”

Icario is a health action company whose solutions seek to deeply understand people by leveraging behavioral and data sciences in order to move them to take action for better health. The early founders of the company recognized the gap between consumer engagement in other industries — travel, retail, and financial services — and identified an opportunity to do the same for healthcare through personalized, multi-channel communications that connect all people to health.

“We are thrilled to welcome the CVC team as Icario’s capital partner,” said Tom Wicka, co-founder of NovuHealth and chairman of Icario. “We have a shared vision for using technology and data to drive consumer behaviors that empower health plans’ quality, assessment, and health action strategies to drive better health outcomes.”

Icario was recently featured on the 2021 Inc. 5000 Regionals: Midwest list, the most prestigious ranking of the fastest-growing private companies in the Midwest. For more information on Icario and its health action capabilities, visit https://icariohealth.com.

TripleTree, LLC served as the exclusive financial advisor to Icario for this transaction. The transaction is subject to regulatory approvals.

About Icario

Icario is the leading health action company focused on connecting people to health. Icario uses pioneering behavioral research, data science and our adaptive multi-channel platform to deliver personalization at scale for the most trusted healthcare organizations in all 50 states, including seven of the 10 largest health plans. Learn more at www.icariohealth.com.

About CVC Capital Partners

CVC is a leading private equity and investment advisory firm with a network of 23 offices throughout Europe, Asia and the US, with approximately US$118 billion of assets under management. Since its founding in 1981, CVC has secured commitments in excess of US$160 billion from some of the world’s leading institutional investors across its private equity and credit strategies. Funds managed or advised by CVC are invested in over 90 companies worldwide, which have combined annual sales of approximately US$100 billion and employ more than 450,000 people.

About CVC Growth Partners

Launched in 2014, CVC Growth Partners is the growth-oriented middle-market technology investment arm of CVC Capital Partners. CVC Growth Partners primarily targets equity investments between $50 million and $250 million in North America and Europe and manages over US$2.5 billion in assets across two dedicated funds. For further information about CVC Growth Partners please visit: www.cvc.com/growth.

BOCA Communications for Icario
[email protected]

Highland, CA, May 04, 2021 (GLOBE NEWSWIRE) — The San Manuel Band of Mission Indians (“San Manuel” or the “Tribe”) and the San Manuel Gaming and Hospitality Authority (“SMGHA”) today announced a definitive agreement for a subsidiary of SMGHA to acquire the Palms Casino Resort (the “Palms”) in Las Vegas, Nevada from Red Rock Resorts, Inc. The transaction is expected to close later in 2021, subject to the receipt of regulatory approvals and other customary closing conditions.  

After 35 years of operating San Manuel Casino in Highland, CA, this announcement reflects a milestone for San Manuel.  

“Today represents an important step for the Tribe and its long-term economic diversification strategy,” said San Manuel Chairman Ken Ramirez. “On behalf of the Tribe, we are thankful for the opportunity to join a community that we have come to know and appreciate.” 

For years, the Tribe has demonstrated an interest in and supported the Las Vegas community through contributions to non-profits and Las Vegas institutions including UNLV’s William F. Harrah College of Hospitality and William S. Boyd School of Law, the Public Education Foundation and Shade Tree Shelter, plus partnerships with the Las Vegas Raiders and Allegiant Stadium, and the Vegas Golden Knights.

“The Palms is a well-designed property which has been beautifully redeveloped and maintained by Red Rock Resorts. Our Board believes that the Palms is a casino resort that many of San Manuel Casino’s loyal guests would enjoy,” said SMGHA Chairwoman Latisha Casas. “We are excited to move forward with this transaction.”   

Jefferies LLC is acting as San Manuel’s financial advisor.  Latham & Watkins LLP and Greenberg Traurig, LLP are acting as the Tribe’s legal counsel.

The Palms, which has been closed for over a year, is located just west of I-15 near the Las Vegas Strip, and includes a casino, approximately 700 hotel rooms and suites, multiple casual and upscale dining options, meeting and convention space, a 2,500-seat theater, pool and spa, other amenities and Palms Place condominiums. 

San Manuel is a top-10 private employer in San Bernardino County in Southern California with more than 4,900 team members. The Tribe currently has a major expansion project underway at San Manuel Casino featuring 432 guest rooms, expanded high-limit gaming, new dining amenities and a special events space. This expansion will add more than 2,000 new jobs by the end of 2021.   

For images and media assets click here.

About the San Manuel Band of Mission Indians 

The San Manuel Band of Serrano Mission Indians is a federally recognized American Indian tribe located near the city of Highland, Calif. The Serrano Indians are the indigenous people of the San Bernardino highlands, passes, valleys and mountains who share a common language and culture. The San Manuel reservation was established in 1891 and recognized as a sovereign nation with the right of self-government. As an indigenous community the origins and history of the San Manuel Band of Mission Indians stem from our relationship with the land and to all who share it. Since ancient times we have expressed ourselves through a culture of giving. Today, San Manuel is able to answer the call of Yawa’ (Serrano word meaning “to act on one’s beliefs”) through partnerships with charitable organizations. We have drawn upon our history, knowledge, expertise and cultural values to direct our philanthropic giving in our local region, as well as to Native American causes nationwide. For more information, visit http://www.sanmanuel-nsn.gov. 

 

Jenna Brady
San Manuel Band of Mission Indians
(909) 855-5646
[email protected]

Boston, May 04, 2021 (GLOBE NEWSWIRE) — Duck Creek Technologies, Inc. (Nasdaq: DCT) (“Duck Creek”), a provider of SaaS-delivered enterprise software to the property & casualty (“P&C”) insurance industry, announced today that it is has introduced a new operational tool for its SaaS customers licensing Duck Creek Policy, Billing, Rating, Claims, Insights, and Producer, the OnDemand Control Hub. The Control Hub is a web interface that enhances carrier IT Operations teams’ abilities to deploy, monitor, and control all their Duck Creek SaaS applications through an intuitive, web-based portal. Within Control Hub, carriers can manage access, roles and permissions for test environment users, control the schedule of their configuration and data updates into production, and view system availability and system health check dashboards, as well as other operational metrics.

OnDemand is Duck Creek’s cloud-based, evergreen SaaS solution for all Duck Creek applications, providing all the services, support, and computing resources carriers need. By combining Duck Creek’s P&C applications and content, the Duck Creek Platform’s low-code configuration tools and open architecture, and SaaS delivery, insurers gain the ability for everyone in their organizations to be more productive and self-reliant in their roles, empowered to move faster, and better positioned to provide a new standard of coverage and experiences that today’s customers expect.

“IAT’s production support team has been using the OnDemand Control Hub during its pilot phase, and we have found the system to be easy to use. Simply put – Control Hub is enabling our DevOps process to be significantly more productive,” said Sean Ferrigan, IT Manager at IAT Insurance Group. “As we continue to grow our business, having quick access to environment statuses and system usage metrics helps get everyone on the same page. Furthermore, the ability to control timing of data updates and get immediate feedback on their success has been very useful and has reduced our reliance on Duck Creek for support, while at the same time reducing the amount of time and effort required by our IT teams.”

“Even in a SaaS model, there are certain tasks that fall on carrier IT teams,” said Tom Carroll, Director of Product Management for SaaS at Duck Creek Technologies. He continued, “With the OnDemand Control Hub, we’re automating both the repetitive and redundant, and some ad-hoc IT tasks, packaging them up together, as well as providing more transparency and visibility into core system applications. The result is that carriers can take action on their own terms and with even more speed than before, and use that time gained back to refocus on innovating.”

“Core system providers are maturing their offerings to put the control of key features such as test user administration into the hands of insurers, while also giving them visibility into the availability of all environments and usage of the applications,” said Karen Furtado, Partner at Strategy Meets Action. “Web-based interfaces such as Duck Creek’s OnDemand Control Hub reflect the next stage of SaaS maturity of core system vendors, and provide the tools needed to help insurers operate more efficiently while having more freedom to do things on their own timelines.”

As Duck Creek continues to scale up their SaaS customer base, the company will continue to invest in the OnDemand Control Hub, providing both support for additional Duck Creek applications, as well as providing additional functionality that will aid their customers in maintaining their existing systems over time and setting them up for success to always be ready to focus on their big strategic initiatives.

About IAT Insurance:

Certified as a Great Place to Work® for the past three years, IAT Insurance Group is a privately owned, specialty insurance company providing property, casualty and surety products for niche markets. IAT goes to market through eight business units – Commercial Transportation, Specialty, Programs, Inland Marine, Excess Casualty Mid-Market, Reinsurance, Surety and Management Liability. The IAT Insurance Group companies are rated A- Excellent by A.M. Best. Connect with IAT Insurance Group on LinkedIn and learn more about the company at iatinsurancegroup.com.

About Duck Creek Technologies:

Duck Creek Technologies (Nasdaq: DCT) is a leading provider of core system solutions to the P&C and General insurance industry. By accessing Duck Creek OnDemand, the company’s enterprise Software-as-a-Service solution, insurance carriers are able to navigate uncertainty and capture market opportunities faster than their competitors. Duck Creek’s functionally-rich solutions are available on a standalone basis or as a full suite, and all are available via Duck Creek OnDemand. For more information, visit www.duckcreek.com.

Media Contact:
Paul Rechichi
Racepoint Global
617-624-3295
[email protected]

Sam A. Shay
Duck Creek Technologies
+1 (857) 201-5784
[email protected]

LOS ANGELES, May 04, 2021 (GLOBE NEWSWIRE) — Sitka Hash House, the legendary Hashish brand founded in 2012, today announced their California launch and the roll-out of exotic, handmade hashish-based products curated for today’s cannabis consumer. Crafted in the Lebanese-Style without solvents, Sitka products retain their terpenes and deliver incomparable flavor. Different from any hashish previously introduced to the market, Sitka has the authentic characteristically cakey texture of handmade, fully cured old-world hash.

“Sitka’s technology, formulas, and craftsmanship are really unique,” says Sitka CEO, Jeff Graham. “The positive reaction received across California is testament to the affordable luxury of our artisanal hashish products.”

“Sitka sets a new benchmark for what California hashish fans expect from a brand,” said Mike Beaudry, Founder and CEO of HERBL, Sitka’s distribution partner. “Sitka has a proven business track record and stellar reputation for their potent and reliable hashish products.”

“Europeans often say Sitka hash beats what they find in the old Amsterdam coffee shops,” commented Sitka co-founder and master hash-maker, Nick Saad. “We ensure that each and every element – cones, filters, weed (kief, flower, trim, oil) – contribute to a great experience.”

Sitka’s California partner is Wine Country cannabis brand, Garden Society, who source organic kief and flower from Sonoma and Mendocino County farms and manufacture Sitka’s legendary hashish products.

Sitka is in production on a series of 60+- second videos featuring Nick Saad: A CRAFTSMAN’S GUIDE TO HASHISH. The Sitka team will share hashish history and today’s hashish lifestyle.

Accessories:

To enhance the smoking experience, Sitka offers handmade glass Hash Domes, hot knives, hash trays, and Sebsi pipes.

SKUs, Pricing, and Availability:

Sitka hashish and hash-infused pre-rolls can be purchased in select dispensaries in California and through our licensed distributor, HERBL. Suggested retail prices are in the range of $10 to $45. To learn more and find retail locations and finely crafted branded merchandise, visit www.Sitkagold.com or follow us on Instagram.

About Sitka Hash House:

Sitka Hash House is a cannabis brand founded in Seattle, WA in 2012 with operations in California and Washington State. Sitka trichome-rich hashish is made for today’s cannabis consumer looking to Discover a New Door to Taste and to Reveal a Path to Wonder. Handmade by craftsmen, Sitka’s full spectrum Lebanese-style traditional hash delivers incomparable taste and experience. The brand creates hashish, hashish-infused products and accessories that enhance any cannabis lifestyle. To learn more, visit www.Sitkagold.com or follow us on Instagram.

About Garden Society:

Women-owned, Garden Society is a craft cannabis company based in Sonoma County, California. Inspired by the surrounding wine country, Garden Society strives for exceedingly great products, made with uncompromising quality, that turn down the daily chaos and turn up the joy. The company’s effect-based, full spectrum edibles and sun-grown pre-roll Rosettes connect responsible farming, sustainable ingredients and strain-specific cannabis. For more information, visit the Garden Society website, or follow on Instagram or Facebook.

About HERBL:
HERBL is California’s largest cannabis distributor and supply chain solutions company servicing more than 850 storefront and non-storefront retail licensees. Founded in 2016, HERBL brings the state’s leading cannabis retailers and top brands together through innovative technology, unparalleled service, and both high-security, state-of-the-art facilities and trucks. HERBL’s team consists of a strong mix of legacy cannabis operators and entrepreneurs alongside distribution and retail experts with extensive experience in large-scale global supply chains. Exclusive brand partners include leaders in flower, vapes, edibles, topicals, pre-rolls, and concentrate. To learn more, visit www.HERBL.com or follow us on Instagram, LinkedIn, Facebook or Twitter.

Media contact:
Heidi Groshelle
Groshelle Communications for Sitka
[email protected]

A video accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c2d4afe6-766d-43a1-a910-fa23e4e95e5f

SALT LAKE CITY, May 04, 2021 (GLOBE NEWSWIRE) — SINTX Technologies, Inc. (www.sintx.com) (NASDAQ: SINT) (“SINTX” or the “Company”), an original equipment manufacturer of silicon nitride ceramic for medical and non-medical applications, announced today multiple U.S. and international patent applications for development of new technologies utilizing the Company’s silicon nitride.

The following expand on several existing antipathogenic and coating-technology patent applications:

• Systems and Methods for Rapid Inactivation of SARS-CoV-2 by Silicon Nitride, Copper and Aluminum Nitride
• Antipathogenic Composites and Devices and Methods of Use Thereof
• Antipathogenic Face Mask
• Systems and Methods for Physical Vapor Deposition of Silicon Nitride Coatings Having Antimicrobial and Osteogenic Enhancements
• Methods of Silicon Nitride Laser Cladding
• Methods for Laser Coating of Silicon Nitride on a Metal Substrate

The patent applications largely relate to the development of antipathogenic and/or osteogenic composite systems, methods, devices, and surface coatings. The technologies can be applied in antipathogenic devices such as face masks and filters, or in medical devices such as orthopedic, wound care dressings, and dental implants. The patent applications are an important milestone in SINTX’s commitment to leverage the inherent antipathogenic and osteogenic properties of silicon nitride in powders and coatings to address viral diseases such as COVID-19 and to improve outcomes in medical device implantations.

About SINTX Technologies, Inc.

SINTX Technologies is an OEM ceramics company that develops and commercializes silicon nitride for medical and non-medical applications. The core strength of SINTX Technologies is the manufacturing, research, and development of silicon nitride ceramics for external partners. The Company presently manufactures silicon nitride powders and components in its FDA registered, ISO 13485:2016 certified, and ASD9100D certified manufacturing facility.

For more information on SINTX Technologies or its silicon nitride material platform, please visit www.sintx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) that are subject to a number of risks and uncertainties. Risks and uncertainties that may cause such differences include, among other things: the patent applications may not be granted or may not afford the protection we are seeking; volatility in the price of SINTX’s common stock; the uncertainties inherent in new product development, including the cost and time required to commercialize such product(s); market acceptance of our products once commercialized; SINTX’s ability to raise funding and other competitive developments. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations, and beliefs. There can be no assurance that any of the anticipated results will occur on a timely basis or at all due to certain risks and uncertainties, a discussion of which can be found in SINTX’s Risk Factors disclosure in its Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 22, 2021, and in SINTX’s other filings with the SEC. SINTX disclaims any obligation to update any forward-looking statements. SINTX undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this report.

Business Inquiries for SINTX:

SINTX Technologies
801.839.3502
[email protected]

Media Inquiries for SINTX:

Amanda Barry
Associate Director, Content and PR
The Summit Group
[email protected]

BEIJING, May 04, 2021 (GLOBE NEWSWIRE) — Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: TYHT), a producer and distributor of Chinese herbal medicines, organic agricultural and hemp products, today announced the Company and Mayah Biological Holdings Limited (“Mayah Biological”), a British Virgin Islands Company headquartered in Taiwan Biomedical Park, had signed a Proposal for Purchase of Equity Interest of Mayah Biological Holding Limited (the “Proposal”), with respect to the potential purchase of at least 51% equity interests in Mayah Biological by the Company.

The parties to the Proposal agreed to sign a definitive agreement after going through the due diligence progress by both parties. There is no guarantee, however, that the parties to the Proposal will enter into a definitive agreement. If a definitive agreement is not entered into for any reason, none of the parties to the Proposal will have any liability to any other party based on anything related to the non-binding terms of the Proposal.

Mayah Biological is a biotechnology company, which focuses on the development of chemical and biomedicine in the pre-clinical and clinical stages. Mayah Biological is committed to developing new biological targets of small molecule and protein medicines for the treatment of tumors, diabetes, and drug abuse.

Mayah Biological has a strong scientific research team which consists of professors in the field of medicine research and development (“R&D”) from prestigious universities in the United States, such as professors of the Department of Molecular and Medical Pharmacology at the University of California, Los Angeles School of Medicine, professors of the Department of Molecular and Cellular Biochemistry at the University of Kentucky Cancer Center, and professors of the Department of Pharmaceutical Sciences at University of Kentucky School of Pharmacy. Each member of the scientific research team has over 30 years of working experience in biotechnology and pharmacy with many scientific research accomplishments.

Mayah Biological currently plans to build over 10 medicine pipelines, covering medicine R&D in the fields of tumor, diabetes and antidote. One drug has completed clinical trial phase 2, one cancer drug is ready for clinical trial phase 2, and three other cancer drugs have completed preclinical preparations to enter clinical trial phase 1. Many drugs in the pipeline are first-in-class drugs, with no similar products in the market. Mayah Biological takes advantages of the combination of years of medicine R&D experience of the scientific research team and AI medicine R&D technology, and is also engaged in the R&D of new me-better medicine with known targets.

By using AI medicine R&D technology and utilizing its scientific research team’s strengths in basic research, medicine design, chemical synthesis, activity testing, animal models, and pathology, Mayah Biological believes it will be able to save about 3-5 years in drug development as compared with traditional medicine R&D companies, decrease the uncertainty of medicine R&D, improve the success rate of medicine R&D, greatly reduce the costs and risks of R&D research, and realize its interest to the most extent.

Mayah Biological is currently introducing medicine pipelines and carrying out follow-up R&D of some pipelines under clinical trials. Mayah Biological believes that its medicines will have broad market prospects and sustainable profitability. For example, Mayah Biological is currently developing proteasome inhibitors and new tumor inhibitors and analgesics: it is estimated that from 2024 to 2031, the total annual sales revenue of proteasome inhibitors for the treatment of prostate cancer will be US$14.611 billion per year, the total sales revenue for the treatment of multiple myeloma will be US$2.081 billion per year, and the total annual sales revenue of new tumor inhibitors and analgesics will be US$3.247 billion per year.

About Shineco, Inc.

Incorporated in Delaware in August 1997 and headquartered in Beijing, China, Shineco is a holding company. Through its subsidiaries and variable interest entities, Shineco undertakes vertically- and horizontally-integrated production, distribution, and sales channels to provide health and well-being focused plant-based products in China. Utilizing modern engineering technologies and biotechnologies, Shineco produces, among other products, Chinese herbal medicines, organic agricultural produce, and specialized textiles. For more information about Shineco, please visit http://tianyiluobuma.com.

Forward-Looking Statements

This press release contains information about
Shineco’s
view of its future expectations, plans and prospects that constitute forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, risks and uncertainties associated with its ability to raise additional funding, its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services,
the successful integration of acquired companies, technologies and assets into its portfolio of products and services, marketing and other business development initiatives, competition in the industry, general government regulation, economic conditions, the impact of the COVID-19 pandemic, dependence on key personnel, the ability to attract, hire and retain personnel who possess the technical skills and experience necessary to meet the requirements of its clients, and its ability to protect its intellectual property. Shineco encourages you to review other factors that may affect its future results in
its
registration statement and in its other filings with the Securities and Exchange Commission, including the risks described under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in
its
annual report on Form 10-K for the fiscal year ended June 30, 2020. The forward-looking statements in this press release
are based
on current expectations and Shineco assumes no obligation to update these forward-looking statements.

For more information, please contact:

Tina Xiao
Ascent Investor Relations LLC
Phone: +1-917-609-0333
Email: [email protected]